NCT04313023: A trial that was reported late by Pulmotect, Inc.
This trial has reported, although it was 207 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04313023 |
|---|---|
| Title | A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 9, 2020 |
| Completion date | July 31, 2021 |
| Required reporting date | July 31, 2022, midnight |
| Actual reporting date | Feb. 23, 2023 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | 207 |